Literature DB >> 9370372

Mutagenesis and ligand modification studies on galanin binding to its GTP-binding-protein-coupled receptor GalR1.

M Berthold1, U Kahl, A Juréus, K Kask, G Nordvall, U Langel, T Bartfai.   

Abstract

In this study, a large number of receptor mutants were generated and several N-terminally modified galanin analogues synthesized to refine the previously proposed binding site model for galanin to its GTP-binding-protein-coupled receptor GalR1. In addition to ligand-binding studies, the functionality of mutant receptors was evaluated by assessing their ability to mediate galaninergic inhibition of isoproterenol-stimulated adenylyl cyclase activity. The His264Ala and Phe282Ala receptor mutants, although deficient in binding in the concentration range of galanin used, remain functional albeit 20-fold less efficient than the wild-type receptor in mediating inhibition of stimulated cAMP production by galanin. The His267Ala mutant is, apart from being deficient in galanin binding, also severely impaired in functional coupling. While His264 and Phe282 seem to be important in forming the binding pocket for galanin, His267 might play a role in forming or stabilizing the active conformation of the GalR1 receptor rather than directly participating in the formation of the binding pocket for galanin. N-terminal carboxylic acid analogues of galanin have low affinity to wild-type GalR1, but substantially increased affinity to the Glu271Lys receptor mutant. This, together with the finding that an alanine substitution of Phe115 in TM III results in a tenfold decrease in affinity for galanin, suggests that the N-terminus of galanin interacts with Phe115. In contrast to the Phe282Ala mutation in TM VII, a conservative mutation of Phe282 to tyrosine did not alter the affinity for galanin. Thus, the interaction between Tyr9 of galanin and Phe282 is likely to be of an aromatic-aromatic nature.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370372     DOI: 10.1111/j.1432-1033.1997.00601.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Generating orally active galanin analogues with analgesic activities.

Authors:  Charles R Robertson; Timothy H Pruess; Erin Grussendorf; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2012-02-28       Impact factor: 3.466

2.  GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome.

Authors:  Jian Zhang; Jianyi Yang; Richard Jang; Yang Zhang
Journal:  Structure       Date:  2015-07-16       Impact factor: 5.006

3.  Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery.

Authors:  Charles R Robertson; Erika Adkins Scholl; Timothy H Pruess; Brad R Green; H Steve White; Grzegorz Bulaj
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

4.  Galanin protects against behavioral and neurochemical correlates of opiate reward.

Authors:  Jessica J Hawes; Darlene H Brunzell; Roopashree Narasimhaiah; Ulo Langel; David Wynick; Marina R Picciotto
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

5.  Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors.

Authors:  Jia Duan; Dan-Dan Shen; Tingting Zhao; Shimeng Guo; Xinheng He; Wanchao Yin; Peiyu Xu; Yujie Ji; Li-Nan Chen; Jinyu Liu; Huibing Zhang; Qiufeng Liu; Yi Shi; Xi Cheng; Hualiang Jiang; H Eric Xu; Yan Zhang; Xin Xie; Yi Jiang
Journal:  Nat Commun       Date:  2022-03-15       Impact factor: 17.694

6.  Mouse Spexin: (I) NMR Solution Structure, Docking Models for Receptor Binding, and Histological Expression at Tissue Level.

Authors:  Matthew K H Wong; Mulan He; Kong Hung Sze; Tao Huang; Wendy K W Ko; Zhao-Xiang Bian; Anderson O L Wong
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-02       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.